# OnCo record rejuv-paed-fertility-male (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/rejuv-paed-fertility-male/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "rejuv-paed-fertility-male" ;
  schema:name "Fertility in boys and young men treated for cancer, including testicular tissue banking"@en ;
  schema:description "Male survivors were about half as likely as their brothers to father a child, and the causes are specific: testicular radiotherapy above 7.5 gray, and high cumulative cyclophosphamide, ifosfamide, procarbazine or cisplatin. A young man with none of those was no less likely than his brother. Sperm banking works; tissue banking before puberty has produced no births."@en ;
  schema:url <https://onco.cc/technologies/rejuv-paed-fertility-male/> ;
  schema:dateModified "2026-10-02"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Semen_cryopreservation> ;
  schema:citation <https://doi.org/10.1200/JCO.2009.24.9037>, <https://doi.org/10.1016/S1470-2045(16)00086-3>, <https://doi.org/10.1093/humrep/dez043>, <https://doi.org/10.1016/S1470-2045(17)30026-8>, <https://doi.org/10.1016/S1470-2045(20)30582-9>, <https://doi.org/10.1001/jama.2013.6296> ;
  onco:status "established" ;
  onco:tag "rejuvenation", "survivorship", "paediatric", "late-effects", "evidence:moderate" ;
  onco:related <https://onco.cc/collections/ighg/>, <https://onco.cc/collections/pancaresurfup/>, <https://onco.cc/trials/ccss/>, <https://onco.cc/ideas/idea-acc-default-fertility-preservation-referral/> ;
  onco:cancers <https://onco.cc/cancers/childhood-cancers/>, <https://onco.cc/cancers/all-leukemia/>, <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/ewing-sarcoma/>, <https://onco.cc/cancers/paediatric-germ-cell-tumours/>, <https://onco.cc/cancers/testicular/> ;
  onco:sections <https://onco.cc/fronts/rejuvenation/>, <https://onco.cc/fronts/supportive-care/>, <https://onco.cc/fronts/hormonal/> ;
  onco:technologies <https://onco.cc/technologies/fertility-preservation/>, <https://onco.cc/technologies/rejuv-paed-pituitary-and-puberty/>, <https://onco.cc/technologies/testosterone-after-cancer-treatment/>, <https://onco.cc/technologies/total-body-irradiation/>, <https://onco.cc/terms/allogeneic-transplant/>, <https://onco.cc/technologies/rejuv-paed-cog-ltfu-guidelines/> ;
  onco:drugs <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/ifosfamide/>, <https://onco.cc/drugs/procarbazine/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/busulfan/> ;
  onco:terms <https://onco.cc/terms/late-effects/>, <https://onco.cc/terms/lymphoma-decision-fertility-timing/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-survivorship/>, <https://onco.cc/bottlenecks/b-toxicity-qol/> .